Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 4

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Dermatologic 4Thoracic 3Gastrointestinal 3Other 2Lymphoid 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Melanoma 2646Lymphoma, T-Cell, Cutaneous 479Skin Neoplasms 408Carcinoma, Non-Small-Cell Lung 377Mycosis Fungoides 330Neoplasms 319Keratosis, Actinic 300Sezary Syndrome 294Breast Neoplasms 285Neoplasm Metastasis 284Carcinoma, Renal Cell 280Lymphoma, Non-Hodgkin 276Lymphoma 263Carcinoma, Basal Cell 262Lymphoma, Large B-Cell, Diffuse 261Leukemia, Lymphocytic, Chronic, B-Cell 261Lymphoma, Follicular 259Hodgkin Disease 247Lymphoma, Mantle-Cell 245Lymphoma, B-Cell, Marginal Zone 245Precursor Cell Lymphoblastic Leukemia-Lymphoma 243Uveal Melanoma 234Burkitt Lymphoma 233Lymphoma, Large-Cell, Immunoblastic 223Colorectal Neoplasms 196Lymphoma, Large-Cell, Anaplastic 190Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 186Ovarian Neoplasms 181Squamous Cell Carcinoma of Head and Neck 180Lung Neoplasms 179

Interventions

Infliximab 2Fecal Microbiota Transplantation 2vedolizumab 1Prednisone 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Loperamide 1LDP-02 1Immunoglobulin G 1Disulfides 1CT-P13 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Colitis × Dermatologic × Clear all
NCT04038619 2026-03-20

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

M.D. Anderson Cancer Center

Phase 1 Recruiting
40 enrolled
BreastDermatologicGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colitis, Diarrhea, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Urogenital Neoplasms, Uterine Neoplasms

NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

NCT06206707 2025-11-17

Immunobiome

University of Aarhus

Phase NA Recruiting
20 enrolled
DermatologicGenitourinary

Colitis, Diarrhea, Kidney Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡